{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T13:23:50Z","timestamp":1780838630585,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,10,26]],"date-time":"2013-10-26T00:00:00Z","timestamp":1382745600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s10147-013-0619-5","type":"journal-article","created":{"date-parts":[[2013,10,25]],"date-time":"2013-10-25T07:45:10Z","timestamp":1382687110000},"page":"601-606","source":"Crossref","is-referenced-by-count":28,"title":["Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy"],"prefix":"10.1007","volume":"19","author":[{"given":"Gouji","family":"Toyokawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Takenoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Toyozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiko","family":"Inamasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyako","family":"Kojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Morodomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyoshi","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukito","family":"Ichinose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,26]]},"reference":[{"key":"619_CR1","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1056\/NEJM196503182721104","volume":"272","author":"IJ Selikoff","year":"1965","unstructured":"Selikoff IJ, Churg J, Hammond EC (1965) Relation between exposure to asbestos and mesothelioma. N Engl J Med 272:560\u2013565","journal-title":"N Engl J Med"},{"key":"619_CR2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1349-7006.2011.02165.x","volume":"103","author":"K Gemba","year":"2012","unstructured":"Gemba K, Fujimoto N, Kato K et al (2012) National survey of malignant mesothelioma and asbestos exposure in Japan. Cancer Sci 103:483\u2013490","journal-title":"Cancer Sci"},{"key":"619_CR3","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa JR, Cheung M, Pei J et al (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43:1022\u20131025","journal-title":"Nat Genet"},{"key":"619_CR4","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.1989.7.8.1157","volume":"7","author":"P Ruffie","year":"1989","unstructured":"Ruffie P, Feld R, Minkin S et al (1989) Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 7:1157\u20131168","journal-title":"J Clin Oncol"},{"key":"619_CR5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-5223(99)70469-1","volume":"117","author":"DJ Sugarbaker","year":"1999","unstructured":"Sugarbaker DJ, Flores RM, Jaklitsch MT et al (1999) Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117:54\u201363 discussion 63\u20135","journal-title":"J Thorac Cardiovasc Surg"},{"key":"619_CR6","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","volume":"12","author":"T Treasure","year":"2011","unstructured":"Treasure T, Lang-Lazdunski L, Waller D et al (2011) Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 12:763\u2013772","journal-title":"Lancet Oncol"},{"key":"619_CR7","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636\u20132644","journal-title":"J Clin Oncol"},{"key":"619_CR8","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1200\/JCO.2000.18.23.3912","volume":"18","author":"JP Steele","year":"2000","unstructured":"Steele JP, Shamash J, Evans MT et al (2000) Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18:3912\u20133917","journal-title":"J Clin Oncol"},{"key":"619_CR9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2008.04.001","volume":"63","author":"J Stebbing","year":"2009","unstructured":"Stebbing J, Powles T, McPherson K et al (2009) The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 63:94\u201397","journal-title":"Lung Cancer"},{"key":"619_CR10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.1999.17.1.25","volume":"17","author":"MJ Byrne","year":"1999","unstructured":"Byrne MJ, Davidson JA, Musk AW et al (1999) Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 17:25\u201330","journal-title":"J Clin Oncol"},{"key":"619_CR11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1745-6673-3-34","volume":"3","author":"A Xanthopoulos","year":"2008","unstructured":"Xanthopoulos A, Bauer TT, Blum TG et al (2008) Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study. J Occup Med Toxicol 3:34","journal-title":"J Occup Med Toxicol"},{"key":"619_CR12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.lungcan.2005.03.029","volume":"49","author":"EH Tan","year":"2005","unstructured":"Tan EH, Szczesna A, Krzakowski M et al (2005) Randomized study of vinorelbine\u2013gemcitabine versus vinorelbine\u2013carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 49:233\u2013240","journal-title":"Lung Cancer"},{"key":"619_CR13","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1378\/chest.108.4.1122","volume":"108","author":"VW Rusch","year":"1995","unstructured":"Rusch VW (1995) A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108:1122\u20131128","journal-title":"Chest"},{"key":"619_CR14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","volume":"15","author":"MJ Byrne","year":"2004","unstructured":"Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15:257\u2013260","journal-title":"Ann Oncol"},{"key":"619_CR15","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/annonc\/mds537","volume":"24","author":"Y Tsutani","year":"2013","unstructured":"Tsutani Y, Takuwa T, Miyata Y et al (2013) Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma. Ann Oncol Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 24:1005\u20131010","journal-title":"Ann Oncol"},{"key":"619_CR16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ctrv.2009.09.003","volume":"36","author":"GL Ceresoli","year":"2010","unstructured":"Ceresoli GL, Zucali PA, Gianoncelli L et al (2010) Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 36:24\u201332","journal-title":"Cancer Treat Rev"},{"key":"619_CR17","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/jjco\/hyi127","volume":"35","author":"R Maruyama","year":"2005","unstructured":"Maruyama R, Shoji F, Okamoto T et al (2005) Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma. Jpn J Clin Oncol 35:433\u2013438","journal-title":"Jpn J Clin Oncol"},{"key":"619_CR18","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/cncr.23337","volume":"112","author":"PA Zucali","year":"2008","unstructured":"Zucali PA, Ceresoli GL, Garassino I et al (2008) Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 112:1555\u20131561","journal-title":"Cancer"},{"key":"619_CR19","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","volume":"30","author":"HL Kindler","year":"2012","unstructured":"Kindler HL, Karrison TG, Gandara DR et al (2012) Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 30:2509\u20132515","journal-title":"J Clin Oncol"},{"key":"619_CR20","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","volume":"7","author":"AK Nowak","year":"2012","unstructured":"Nowak AK, Millward MJ, Creaney J et al (2012) A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. J Thorac Oncol 7:1449\u20131456","journal-title":"J Thorac Oncol"},{"key":"619_CR21","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cncr.23617","volume":"113","author":"DM Jackman","year":"2008","unstructured":"Jackman DM, Kindler HL, Yeap BY et al (2008) Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 113:808\u2013814","journal-title":"Cancer"},{"key":"619_CR22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/JTO.0b013e318191520c","volume":"4","author":"SS Ramalingam","year":"2009","unstructured":"Ramalingam SS, Belani CP, Ruel C et al (2009) Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 4:97\u2013101","journal-title":"J Thorac Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-013-0619-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-013-0619-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-013-0619-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T09:00:52Z","timestamp":1564563652000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-013-0619-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,26]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["619"],"URL":"https:\/\/doi.org\/10.1007\/s10147-013-0619-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,26]]}}}